Rescues On Reperfusion Damage In Cerebral Infarction by Nelonemdaz
Status:
Not yet recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety of Neu2000, a multi-target drug designed to prevent both NMDA
receptor-mediated excitotoxicity and free radical toxicity, will be investigated in acute
ischemic stroke patients receiving endovascular treatment to remove clot within 12 hours
following stroke onset. Neu2000KWL will be administered before endovascular treatment.